Trevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright started coverage on shares of Trevi Therapeutics (NASDAQ:TRVI) in a report published on Friday, Marketbeat reports. The brokerage issued a buy rating and a $6.00 target price on the stock.

TRVI has been the subject of several other research reports. EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a strong-buy rating in a research report on Monday, August 19th. Raymond James initiated coverage on shares of Trevi Therapeutics in a research report on Friday. They issued an outperform rating and a $9.00 price target for the company. Needham & Company LLC reaffirmed a buy rating and issued a $8.00 price target on shares of Trevi Therapeutics in a research report on Wednesday, May 8th. Finally, Rodman & Renshaw initiated coverage on shares of Trevi Therapeutics in a research report on Thursday, June 13th. They issued a buy rating and a $7.00 price target for the company. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Trevi Therapeutics has a consensus rating of Buy and a consensus price target of $7.80.

Trevi Therapeutics Trading Up 8.6 %

TRVI stock opened at $3.16 on Friday. Trevi Therapeutics has a 12 month low of $0.97 and a 12 month high of $4.00. The company has a 50-day moving average price of $2.84 and a 200 day moving average price of $2.86. The stock has a market cap of $229.38 million, a PE ratio of -9.29 and a beta of 0.96.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). During the same period in the previous year, the firm earned ($0.07) EPS. Sell-side analysts forecast that Trevi Therapeutics will post -0.46 EPS for the current year.

Insider Buying and Selling

In related news, insider Thomas Sciascia sold 18,660 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $2.76, for a total transaction of $51,501.60. Following the completion of the transaction, the insider now owns 220,315 shares in the company, valued at approximately $608,069.40. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 23,315 shares of company stock worth $65,123 in the last 90 days. 24.37% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD acquired a new position in Trevi Therapeutics during the 1st quarter valued at approximately $47,000. Hsbc Holdings PLC acquired a new position in Trevi Therapeutics during the 2nd quarter valued at approximately $61,000. The Manufacturers Life Insurance Company increased its stake in Trevi Therapeutics by 87.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock valued at $73,000 after purchasing an additional 11,450 shares in the last quarter. American Century Companies Inc. increased its stake in Trevi Therapeutics by 17.1% during the 2nd quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock valued at $161,000 after purchasing an additional 7,902 shares in the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new position in Trevi Therapeutics during the 1st quarter valued at approximately $208,000. Institutional investors and hedge funds own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.